BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Enzon Offloads Specialty Arm to Sigma-Tau for up to $327M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Enzon Offloads Specialty Arm to Sigma-Tau for up to $327M
Nov. 10, 2009
By
Catherine Hollingsworth
No Comments
Enzon Pharmaceuticals Inc. has agreed to sell its specialty pharmaceutical business to Italian-owned Sigma-Tau Pharmaceuticals Inc. for $300 million plus up to an additional $27 million based on milestones. (BioWorld Today)
BioWorld